JP2012511586A5 - - Google Patents

Download PDF

Info

Publication number
JP2012511586A5
JP2012511586A5 JP2011540882A JP2011540882A JP2012511586A5 JP 2012511586 A5 JP2012511586 A5 JP 2012511586A5 JP 2011540882 A JP2011540882 A JP 2011540882A JP 2011540882 A JP2011540882 A JP 2011540882A JP 2012511586 A5 JP2012511586 A5 JP 2012511586A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
glp
human
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011540882A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012511586A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/067469 external-priority patent/WO2010068735A1/en
Publication of JP2012511586A publication Critical patent/JP2012511586A/ja
Publication of JP2012511586A5 publication Critical patent/JP2012511586A5/ja
Pending legal-status Critical Current

Links

JP2011540882A 2008-12-10 2009-12-10 医薬組成物 Pending JP2012511586A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US12122908P 2008-12-10 2008-12-10
US61/121,229 2008-12-10
US15090909P 2009-02-09 2009-02-09
US61/150,909 2009-02-09
US16399509P 2009-03-27 2009-03-27
US61/163,995 2009-03-27
US23872309P 2009-09-01 2009-09-01
US61/238,723 2009-09-01
PCT/US2009/067469 WO2010068735A1 (en) 2008-12-10 2009-12-10 Pharmaceutical compositions

Publications (2)

Publication Number Publication Date
JP2012511586A JP2012511586A (ja) 2012-05-24
JP2012511586A5 true JP2012511586A5 (https=) 2013-01-31

Family

ID=42243062

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011540882A Pending JP2012511586A (ja) 2008-12-10 2009-12-10 医薬組成物

Country Status (14)

Country Link
US (3) US8748377B2 (https=)
EP (1) EP2373681B1 (https=)
JP (1) JP2012511586A (https=)
CY (1) CY1118731T1 (https=)
DK (1) DK2373681T3 (https=)
ES (1) ES2620610T3 (https=)
HR (1) HRP20170478T1 (https=)
HU (1) HUE031900T2 (https=)
LT (1) LT2373681T (https=)
PL (1) PL2373681T3 (https=)
PT (1) PT2373681T (https=)
SI (1) SI2373681T1 (https=)
SM (1) SMT201700189T1 (https=)
WO (1) WO2010068735A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8748377B2 (en) 2008-12-10 2014-06-10 Glaxosmithkline Llc Pharmaceutical compositions
JP2013525491A (ja) * 2010-05-04 2013-06-20 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 心血管障害を治療または予防し心血管保護を提供する方法
TW201315742A (zh) 2011-09-26 2013-04-16 Novartis Ag 治療代謝病症之雙功能蛋白質
HRP20251088T1 (hr) 2012-07-01 2025-11-07 Novo Nordisk A/S Upotreba dugodjelujućih peptida glp‑1
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
HK1211232A1 (en) 2012-12-21 2016-05-20 Sanofi Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists
US9849066B2 (en) 2013-04-24 2017-12-26 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
LT3004155T (lt) 2013-05-28 2021-12-27 Takeda Pharmaceutical Company Limited Peptidų junginys
US20140378374A1 (en) * 2013-06-21 2014-12-25 Glaxosmithkline Intellectual Property (No.2) Limited Methods of treatment
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
EP3160491A4 (en) * 2014-06-25 2018-01-17 GlaxoSmithKline LLC Pharmaceutical compositions
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
WO2017204219A1 (ja) 2016-05-24 2017-11-30 武田薬品工業株式会社 ペプチド化合物
MY200364A (en) 2017-09-22 2023-12-21 Regeneron Pharma Glucagon-like peptide 1 receptor agonists and uses thereof
JP7148605B2 (ja) 2017-10-12 2022-10-05 ノヴォ ノルディスク アー／エス 医学療法におけるセマグルチド
CN120187750A (zh) 2022-09-21 2025-06-20 瑞泽恩制药公司 治疗肥胖、糖尿病和肝功能障碍的方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
ATE164852T1 (de) * 1990-01-24 1998-04-15 Douglas I Buckley Glp-1-analoga verwendbar in der diabetesbehandlung
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
WO1998005351A1 (en) 1996-08-08 1998-02-12 Amylin Pharmaceuticals, Inc. Methods for regulating gastrointestinal motility
US6277819B1 (en) 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
US6380357B2 (en) 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
US6284725B1 (en) 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
US7259136B2 (en) 1999-04-30 2007-08-21 Amylin Pharmaceuticals, Inc. Compositions and methods for treating peripheral vascular disease
CA2363712C (en) 1999-05-17 2011-05-10 Conjuchem Inc. Long lasting insulinotropic peptides
EP1076066A1 (en) * 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
ATE397938T1 (de) 2000-05-19 2008-07-15 Amylin Pharmaceuticals Inc Behandlung des akuten koronaren syndroms mit glp- 1
AU2002213441B2 (en) 2000-10-12 2006-10-26 Genentech, Inc. Reduced-viscosity concentrated protein formulations
WO2002034285A2 (en) 2000-10-20 2002-05-02 Coolidge Thomas R Treatment of hibernating myocardium and diabetic cardiomyopathy with a glp-1 peptide
BR0116024A (pt) 2000-12-07 2005-12-13 Lilly Co Eli Proteìna de fusão heteróloga e uso da mesma
US7259233B2 (en) 2000-12-13 2007-08-21 Eli Lilly And Company Chronic treatment regimen using glucagon-like insulinotropic peptides
AR036711A1 (es) 2001-10-05 2004-09-29 Bayer Corp Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
CA2463908A1 (en) 2001-10-18 2003-04-24 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
EP2261250B1 (en) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
AU2002364587A1 (en) 2001-12-21 2003-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
MXPA04006679A (es) 2002-01-08 2004-11-10 Lilly Co Eli Analogos extendidos de peptido-1 de tipo glucagon.
WO2003084563A1 (en) 2002-04-04 2003-10-16 Novo Nordisk A/S Glp-1 agonist and cardiovascular complications
US7790681B2 (en) 2002-12-17 2010-09-07 Amylin Pharmaceuticals, Inc. Treatment of cardiac arrhythmias with GLP-1 receptor ligands
AU2003297356A1 (en) 2002-12-17 2004-07-14 Amylin Pharmaceuticals, Inc. Prevention and treatment of cardiac arrhythmias
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
ES2567634T3 (es) 2004-02-09 2016-04-25 Human Genome Sciences, Inc. Proteínas de fusión de albúmina
JP2008501765A (ja) 2004-06-11 2008-01-24 ノボ　ノルディスク　アクティーゼルスカブ Ｇｌｐ−１アゴニストを用いた薬剤誘発性肥満の中和
WO2006010143A2 (en) 2004-07-13 2006-01-26 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
KR20070090036A (ko) 2004-12-22 2007-09-04 센토코 인코포레이티드 Ｇｌｐ-1 작용제, 조성물, 방법 및 용도
WO2006073890A2 (en) 2004-12-24 2006-07-13 Amylin Pharmaceuticals, Inc. Use of glp-1 and agonists thereof to prevent cardiac myocyte apoptosis
EP2258382A3 (en) 2005-03-31 2014-05-14 Amylin Pharmaceuticals, LLC Amylin and amylin agonists for treating psychiatric diseases and disorders
ES2365410T3 (es) * 2005-04-08 2011-10-04 Amylin Pharmaceuticals, Inc. Formulaciones farmacéuticas que comprenden péptido de incretina y un disolvente polar aprótico.
WO2006110887A2 (en) 2005-04-11 2006-10-19 Amylin Pharmaceuticals, Inc Use of glp-1, exendin and agonists thereof to delay or prevent cardiac remodeling
ES2586236T3 (es) 2005-11-04 2016-10-13 Glaxosmithkline Llc Procedimientos para administrar agentes hipoglucémicos
US20100022457A1 (en) 2006-05-26 2010-01-28 Bristol-Myers Squibb Company Sustained release glp-1 receptor modulators
AU2007267833B2 (en) 2006-05-26 2012-07-26 Amylin Pharmaceuticals, Llc Composition and methods for treatment of congestive heart failure
AU2007275294A1 (en) 2006-07-18 2008-01-24 Centocor, Inc. Human GLP-1 mimetibodies, compositions, methods and uses
EP2068910A2 (en) 2006-08-04 2009-06-17 Amylin Pharmaceuticals, Inc. Use of exendins and exendin agonists and glp-1 receptor agonists for altering lipoprotein particle size and subclass composition
TWI430806B (zh) * 2006-09-13 2014-03-21 Smithkline Beecham Corp 用於投與長效降血糖藥劑之方法
EP2163243A1 (en) 2008-09-12 2010-03-17 Biocompatibles UK Limited Treatment of acute myocardial infarction (AMI) using encapsulated cells encoding and secreting GLP-1 peptides or analogs thereof
US8748377B2 (en) 2008-12-10 2014-06-10 Glaxosmithkline Llc Pharmaceutical compositions

Similar Documents

Publication Publication Date Title
JP2012511586A5 (https=)
Kumar et al. Therapeutic molecules against type 2 diabetes: What we have and what are we expecting?
HRP20170478T1 (hr) Farmaceutski pripravci albiglutida
Cvetković et al. Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea)
Choe et al. Peptidyl and non-peptidyl oral glucagon-like peptide-1 receptor agonists
EP2324853B1 (en) Lixisenatide as add-on to metformin in the treatment of diabetes type 2
JP2013518035A (ja) 代謝症候群を処置するための医薬組成物
WO2014177623A1 (en) Novel administration regime
US8003605B2 (en) Minimising body weight gain in insulin treatment
WO2008071010A1 (en) Combination treatments with selected growth/hormone regulatory factors for diabetes and related diseases
Stubbs et al. Diabetes medication pharmacology
Sisson Liraglutide: clinical pharmacology and considerations for therapy
US20250319163A1 (en) Treatment of type 2 diabetes mellitus
JP2024150496A (ja) インスリンまたはインスリン類似体と組み合わせたグルコキナーゼ活性化薬の治療的使用
EP1971363A1 (en) Combination treatments with gastrin agonists for diabetes and related diseases
Gallwitz Glucagon-like peptide-1 as a treatment option for type 2 diabetes and its role in restoring beta-cell mass
Lam et al. Exenatide: a novel incretin mimetic agent for treating type 2 diabetes mellitus
Chia et al. Role and development of GLP-1 receptor agonists in the management of diabetes
Pitocco et al. Unmet needs among patients with type 2 diabetes and secondary failure to oral anti-diabetic agents
Groves et al. Standard and novel treatment options for metabolic syndrome and diabetes mellitus
Imam Diabetes: a new horizon and approach to management
Klonoff Incretin therapy for type 2 diabetes mellitus
Rauseo et al. Management of type 2 diabetes in geriatric patients
Thongtang et al. Incretins: the novel therapy of type 2 diabetes
McCall Combination therapy for treatment of type 2 diabetes